Rifapentine With and Without Moxifloxacin for Pulmonary Tuberculosis in People With Human Immunodeficiency Virus (S31/A5349)
InfectologiaSobre o estudo
- Desenho
- Ensaio clínico randomizado
- Nível de evidência
- 2 · Nova evidência
- Revista
- Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
- Publicado em
- 8 fev 2023
- Citações
- 15
O resumo deste estudo é do publisher e não tem licença aberta: por isso mostramos aqui só os dados do estudo, e o texto fica na fonte original, nos links abaixo.
O estudo original
Rifapentine With and Without Moxifloxacin for Pulmonary Tuberculosis in People With Human Immunodeficiency Virus (S31/A5349)
April C Pettit, Patrick P J Phillips, Ekaterina Kurbatova, Andrew Vernon, Payam Nahid, Rodney Dawson, Kelly E Dooley, Ian Sanne, Ziyaad Waja, Lerato Mohapi et al.
Descritores MeSH
- Tuberculosis, Pulmonary
- HIV Infections
- Tuberculosis
- Cyclopropanes
- Drug Therapy, Combination
- HIV
- Humans
- Isoniazid
- Rifampin
- Moxifloxacin
Veja também
Estudos relacionados
- Pharmacokinetics of rifampicin and isoniazid in patients with HIV-tuberculosis coinfection receiving efavirenz-based antiretroviral treatment: an ANRS12292-RIFAVIRENZ sub-study
- Efavirenz Pharmacokinetics and Human Immunodeficiency Virus Type 1 (HIV-1) Viral Suppression Among Patients Receiving Tuberculosis Treatment Containing Daily High-Dose Rifapentine
- Effect of efavirenz-based antiretroviral therapy and high-dose rifampicin on the pharmacokinetics of isoniazid and acetyl-isoniazid
- Effect of rifampicin and efavirenz on moxifloxacin concentrations when co-administered in patients with drug-susceptible TB